STOCKS TELEGRAPH

Tag: BCDA Stock

  • BioCardia (BCDA) Stock Sees Sharp Rise After A Regulatory Approval

    BioCardia (BCDA) Stock Sees Sharp Rise After A Regulatory Approval

    BioCardia, Inc. (NASDAQ: BCDA) shares has increased significantly this morning since the company received recent regulatory approval. As of the most recent update, BCDA stock was trading at $3.57 with a 62.27% rise.

    This increase follows the company’s press release stating that the FDA in the United States has given the business permission to commercialize its Morph DNA Steerable Introducer product family in accordance with the Federal Food, Drug, and Cosmetic Act’s general regulations.

    FDA Clears New Product Line for Market

    With FDA approval, the Morph DNA Steerable Introducer product line makes it easier to insert different medical devices into the heart chambers or peripheral vasculature, including guidewires, balloon dilatation catheters, and other therapeutic devices.

    The 16 distinct goods covered by the clearance have diameters that correspond to French introducer sheaths 5, 6, 7, and 8, and lengths that range from 30 to 90 centimeters. These products are expected to cover a broad range of therapeutic applications in several disciplines, including radiography, cardiac electrophysiology, interventional cardiology, and vascular surgery.

    Expanding Clinical Applications and Market Reach

    The Morph DNA Steerable Introducer family is expected to enhance several advanced medical procedures, including peripheral vascular intervention, renal denervation, endovascular aortic repair, carotid artery stenting, and atrial fibrillation mapping and ablation.

    BioCardia’s earlier Morph product, limited to a single diameter, has already been employed in approximately 12,000 procedures across these applications. The new, more advanced product line aims to expand its reach to an even broader range of clinical practices, providing value to both physicians and patients.

    Market Potential and Product Features

    BioCardia estimates that over a million procedures conducted annually in the United States could benefit from these newly approved products, which are expected to be priced at a starting list price of $1,000.

    Initially developed to meet the company’s own needs in cell therapy procedures, the Morph DNA steerable introducer family features innovative design elements, such as bidirectional steering, enhanced torque response, ergonomic actuation, and an adjustable brake for fine control. These features are poised to address common challenges and improve procedural outcomes in various cardiovascular and vascular interventions.

  • BioCardia (BCDA) Shares Climb In Extended Trading Session

    BioCardia (BCDA) Shares Climb In Extended Trading Session

    Shares of BioCardia, Inc. (NASDAQ: BCDA) experienced a notable rise during the extended trading session on Wednesday, following recent advancements. As of the latest update, BCDA stock increased by 10.92% on the US stock charts, reaching a price of $3.15.

    Patent Grant and Technological Advancement

    The USPTO has awarded Patent No. 12,036,371, entitled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” to BioCardia, the company recently stated. This patent is valid until 2035 and is based on the company’s Morph DNA technology.

    The invention pertains to medical methods for transseptal access to the heart using steerable introducers, thereby enhancing the value of BioCardia’s current and future products in this crucial market.

    Market Impact and Technological Innovation by BioCardia

    This technology will be beneficial to transseptal delivery procedures including repair of patent foramen ovale and atrial septal defect, ablation of atrial fibrillation, percutaneous mitral valve repair, percutaneous placement of left ventricular assist device, and closure of the left atrial appendage.

    The worldwide market for transseptal access systems is anticipated to grow from $941.3 million in sales in 2022 to $2.1 billion by 2033 at a Compound Annual Growth Rate (CAGR) of 7.3%. The Morph DNA designs enable tensioning elements within the catheter to rotate around the catheter shaft, ensuring consistent performance in any direction.

    The design’s resemblance to a double helix, akin to a strand of DNA, inspired the name. This innovative approach aims to facilitate smooth navigation and prevent the “whip” effect, where mechanical forces cause a sudden shift in catheter orientation.

    Future Prospects and Market Expansion

    BioCardia’s biotherapeutic interventions for heart failure, refractory angina, and acute myocardial infarction are expected to utilize this introducer technology platform moving forward. This sophisticated solution addresses a longstanding technical challenge, enhancing physician control during procedures.

    BioCardia is dedicated to providing or partnering to deliver this solution for the approximately 500,000 transseptal procedures conducted annually in the United States, as well as for other vascular access markets that can benefit from the advantages of their patented technology.

  • Here’s the Reason of Soaring Premarket Stock of Biocardia, Inc. (BCDA)

    Here’s the Reason of Soaring Premarket Stock of Biocardia, Inc. (BCDA)

    Biocardia, Inc. (BCDA) is a leading regenerative therapeutics firm engaged in the development of therapeutics for cardiovascular diseases. The lead pipeline candidate of the company is CardiAMP used in treating heart attack and chronic myocardial ischemia. Bone marrow-derived mesenchymal stem cell therapy is another lead candidate for its therapeutic potential against ischemic systolic myocardial infractions.

    The price of BCDA stock during the regular trading on February 2, 2022, was $1.57 with a dip of 6.55%. At last check in the premarket on February 3, 2022, the stock price rocketed by 27.3%.

    Events and Happenings

    On February 3, 2022, BCDA updated about the grant of Breakthrough Device Designation by the FDA to the lead candidate CardiAMP Cell Therapy System. It is considered to be the pioneer receiver of cardiac cell therapy by FDA.

    BCDA: CEO Comments

    Speaking at the momentous occasion, BCDA CEO Peter Altman stated that the previously published results of the clinical studies had met the company’s expectations. He further added that the company had added three elements to enhance its success probability after certain discrepancies in the previous trials.

    On January 10, 2022, BCDA reported that the Executive management participated at the following virtual investor conferences.

    • The H.C. Wainwright BioConnect Virtual Conference on January 10-13
    • The Biotech Showcase taking place January 10-12

    On December 15, 2021, BCDA updated about its entry into a long-term contract for a new building location. The facility provides growth opportunities to the production of the company’s product candidates.

    BCDA: Key Financials

    On November 10, 2021, BCDA released its financial results for the third quarter of 2021. Some of the important updates are as follows

    Revenue

    Revenue recorded in Q3 2021 was $0.82 million compared to $0.03 million in the same period of 2020. The analyst’s estimate of the revenue for the quarter was $0.04 million.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $2.7 million or $0.16 compared to $3.8 million or $0.30 per share in the same quarter of 2020. The company topped the analysts’ consensus estimates of $0.21 net loss by $0.05.

    Conclusion

    BCDA stock downplayed by 55% from the past few months as the companies are showing decelerating trend due to pandemics. The company’s recent premarket leap came after the FDA’s approval of breakthrough device designation by CardiAMP. The company’s stock is outperforming and is capable to attract investments.

  • Biocardia Inc. (BCDA) Stock Took a Leap in the Pre-Market Despite any Visible Reason

    Biocardia Inc. (BCDA) is an innovative regenerative therapeutics company that develops medication for different cardiovascular indications. One of the lead product candidates of the company is CardiAMP used for the treatment of myocardial infarction and chronic myocardial ischemia. Another product candidate in Phase 1/2 trials is NK1R+ allogeneic bone marrow-derived mesenchymal stem cell therapy for the ischemic systolic myocardial infraction.

    The price of BCDA stock during the regular trading inclined 6.16% on December 22, 2021, to $2.24. At last check in the premarket, the stock was further up by 3.57%.

    Events and Happenings

    On December 15, 2021, BCDA announced its entry into a long-term lease agreement for a new facility in California. The purpose of this facility was to provide sustenance to the production of the company’s cell and device-related product candidates across BCDA’s therapeutic ventures.

    Key Financials

    On November 10, 2021, BCDA announced its financial results for the third quarter of 2021. Some of the key highlights are as follows

    Revenue

    Revenue reported for the third quarter of 2021 was $0.82 million and it increased in comparison to $0.03 million for the same quarter of 2020.

    Net Loss per Share

    Basic and diluted net loss per share decreased over the period of the year from $3.8 million or $0.30 per share in Q3 2020 to $2.7 million or $0.16 per share for Q3 2021.

    Total Assets

    Total assets of the company were reported to be $17 million n Q3 2021 as compared to the same period prior year when the assets were $9.5 million.

    On October 21, 2021, BCDA reported the treatment of its initial subject for Phase 3 clinical trials of CardiAMP Cell Therapy for patients with no option but to bear the angina pain. The trial will approximately enroll 343 patients. On October 12, 2021, BCDA reported about the issuance of Patent for Multi-Directional Steerable Catheter which safeguards the Helix Biotherapeutic Delivery System and improves the delivery capacity of the system.

    On October 06, 2021, BCDA reported about its participation in the Virtual A.G.P Biotech & Specialty Pharma Conference held on October 13, 2021. On September 10, 2021, BCDA reported the presentation of its CardiAMP Cell Therapy data at the Heart Failure Society of America Annual Meeting 2021 on September 11. On September 9, 2021, BCDA reported about its presentation at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference held on September 13-15, 2021.

    Conclusion

    The stock of BCDA inclined 9% from the past month which shows that the investors are putting their trust in the company’s strategies despite any clear reason. The company, through its CardiAMP cell therapy, is making a mark in the healthcare department.

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.